Please check your internet connection and try again.
# Rizatriptan
## Overview
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist (triptan) used for the acute treatment of migraine. It exhibits high oral bioavailability and faster onset compared to earlier-generation triptans.
## Primary Indications
Acute treatment of migraine attacks with or without aura in adults and pediatric patients (aged 6 to 17 years).
## Adult Dosing
* **Initial Dose:** 5 mg or 10 mg (10 mg provides greater efficacy).
* **Dosing Interval:** If the migraine returns or fails to respond, a second dose may be taken at least 2 hours after the first.
* **Maximum Daily Dose:** Do not exceed 30 mg in a 24-hour period.
## Pediatric Dosing
* **Patients 6 to 17 years (weight-based):**
* **Weight < 40 kg:** 5 mg single dose.
* **Weight ≥ 40 kg:** 10 mg single dose.
* **Maximum Daily Dose:** Only one dose per 24-hour period is recommended in children and adolescents. Safety of repeat dosing has not been established in this population.
## Dose Adjustments
* **Renal/Hepatic Impairment:** Generally not required, but consider lower doses in patients with moderate hepatic impairment.
* **Propranolol Interaction:** Patients taking propranolol should use the 5 mg dose. The maximum daily dose for these patients is 15 mg (three 5 mg doses), with at least 2 hours between doses.
## Contraindications
* History of ischemic heart disease, coronary artery vasospasm (Prinzmetal’s angina), or MI.
* Uncontrolled hypertension.
* History of stroke or transient ischemic attack (TIA).
* Hemiplegic or basilar migraine.
* Peripheral vascular disease or ischemic bowel disease.
* Administration within 24 hours of another 5-HT1 agonist or ergotamine-type derivative.
* Use within 2 weeks of discontinuing a monoamine oxidase inhibitor (MAOI).
## Adverse Effects
* **Common:** Paresthesia, dizziness, somnolence, fatigue, and dry mouth.
* **Serious:** Coronary vasospasm, myocardial infarction, arrhythmias, and serotonin syndrome (rarely, when used with SSRIs/SNRIs). Chest tightness or pressure is common but must be evaluated to rule out cardiac ischemia.
## Key Drug Interactions
* **MAOIs:** Risk of increased rizatriptan plasma concentrations.
* **Propranolol:** Increases rizatriptan levels; requires dose reduction as noted above.
* **SSRIs/SNRIs:** Potential for serotonin syndrome (use with caution).
* **Ergotamines:** Wait at least 24 hours between administration.
## Monitoring
* Monitor blood pressure periodically, especially in patients with cardiovascular risk factors.
* Assess for chest, jaw, or neck pain after initial dosing to rule out cardiac etiology.
* Monitor for signs/symptoms of serotonin syndrome if combined with other serotonergic medications.
## Clinical Pearls
* **Patient Education:** Advise patients to take the medication as soon as the migraine starts.
* **Oral Disintegrating Tablets (ODT):** These are meant for direct oral administration; they do not require water but must be handled with dry hands.
* **Medication Overuse Headache (MOH):** Avoid over-reliance on triptans; restrict usage to fewer than 10 days per month to prevent rebound headaches.
* **Administration:** Efficacy is documented; if a patient does not respond to the first dose, the second dose is unlikely to provide relief for that specific attack. Seek alternative therapies.
***
**Educational Disclaimer:** This information is for educational purposes only and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and patient-specific guidelines (e.g., package inserts or databases like Lexicomp/UpToDate) before administering medication.
